A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.

CompletadoFase 3ClinicalTrials.gov

ID: NCT00736099Tipo: INTERVENTIONALInicio: 1 de ago de 2008

Traducción no disponible, mostrando original

Resumen

The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment. The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 82 YearsSexo: ALL

Criterios de inclusión

Signed and dated written informed consent in accordance with the GCP and local legislation.
Patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication.

Criterios de exclusión

Patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial.
Pre-menopausal women (last menstruation =\< 1 year prior to signing informed consent) who:
are nursing or pregnant,
or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of birth control) and vasectomised partners. No exception will be made.
Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation.
Drug abuse which, in the opinion of the investigator, would interfere with trial participation.
Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.

Intervenciones

drug

linagliptine 5 mg

safety and efficacy of linagliptine 5 mg open label

drug

linagliptine 5 mg and pioglitazone 30 mg

efficacy and safety of the combination linagliptine and pioglitazone

Ubicaciones

1218.40.54002 Boehringer Ingelheim Investigational Site

Capital Federal, Argentina

1218.40.54010 Boehringer Ingelheim Investigational Site

Capital Federal, Argentina

1218.40.54011 Boehringer Ingelheim Investigational Site

Mendoza, Argentina

1218.40.54015 Boehringer Ingelheim Investigational Site

Parque Velez Sarfield, Argentina

Patrocinadores

PrincipalBoehringer Ingelheim

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A 78 Week Open Label Extension to Trials Assessing the Sa... | EligiMed